Trial Profile
A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 May 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Gimeracil/oteracil/tegafur
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Aug 2015 Status changed from active, no longer recruiting to completed according to results published in the Lung Cancer.
- 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 20 Dec 2011 New trial record